东菱迪芙治疗腔隙性脑梗塞后血浆D-二聚体及纤维蛋白原变化  

Changes of plasma D-Dimer and fibrinogen in patients with lacunar cerebral infarction after treatment with batroxobin:A comparative analysis

作　　者：唐海英[1] 吴秀英[1] 王芬蝶[1] 

机构地区：[1]苏州大学附属第一医院老年科,江苏省苏州市215006

出　　处：《军医进修学院学报》2009年第2期148-149,共2页Academic Journal of Pla Postgraduate Medical School

摘　　要：目的:观察东菱迪芙治疗腔隙性脑梗塞患者后血浆D-二聚体(D-Dimer)及纤维蛋白原(FIB)变化。方法:将120例腔梗患者随机分为东菱迪芙组和常规治疗组,各60例。两组均给予神经细胞营养药和常规药物,而东菱迪芙组在第1,第3,第5,第7天加用东菱迪芙治疗;同时设有急性脑梗塞(ACI)组30例,并设正常对照组30例。测定治疗前后血浆D-二聚体和FIB水平。结果:治疗前腔梗患者的血浆D-二聚体水平显著低于急性脑梗塞患者(P<0.05);东菱迪芙治疗后第7天,D-二聚体水平明显高于治疗前(P<0.05),FIB明显降低(P<0.05);第14天,D-二聚体与治疗前差异不显著(P>0.05)。结论:东菱迪芙使腔隙性脑梗塞患者纤溶活性增强,凝血活性相对减弱,促进微血栓溶解。Objective： To observe the changes of plasma D-Dimer and fibrinogen （FIB） in patients with lacunar cerebral infarction （LI） after treatment with Batroxobin. Methods： A total of 120 patients with LI were randomly divided into Batroxobin treatment group （n = 60） and control group （n = 60） and treated with neurophic and normal drugs. Batroxobin was used in Batroxobin treatment group on days 1, 3, 5, and 7. Thirty patients with acute cerebral infarction served as treatment group, 30 per- sons served as control group. Levels of D-Dimer and FIB were measured in 120 patients before and after treatment. Results： Before treatment, the levels of D-Dimer were lower in patients with LI than in patients with acute cerebral infarction （ P 〈 0.05 ） and there was no significant difference between patients with LI and controls （ P 〉 0. 05 ）. The D-Dimer level was higher and FIB level was lower 7 days after treatment with Batroxobin than before treatment with Batroxnbin （P 〈0. 05）. The D-Dimer level was similar 14 days after treatment with Batroxobin to that before treatment with Batroxobin （P 〉 0.05）. Conclusion： Batroxobin increases fibrinolytic activity, reduces coagulation activity, and accelerates thrombolvsis in patients with LI.

关 键 词：东菱迪芙 脑梗塞 D-二聚体 纤维蛋白原 

分 类 号：R743.33[医药卫生—神经病学与精神病学]